Health related quality of life in patients having schizophrenia negative symptoms – a systematic review

References

• National Institute of Mental Health. Schizophrenia. 2009 [Last Revised 2016 Feb; NIH Publication No. 15-3517. Retrieved from: https://www.nimh.nih.gov/health/publications/schizophrenia-booklet/index.shtml.
   Google Scholar
• Burton N. Living with Schizophrenia. Great Britain: Acheron Press; 2012, 1.
   Google Scholar
• Kirkpatrick B, Fenton WS, Carpenter WT Jr., et al. The NIMH-MATRICS consensus statement on negative symptoms. Schizophr Bull. 2006;32(2):214–10.
   PubMed Web of Science ®Google Scholar
• Blanchard JJ, Kring AM, Horan WP, et al. Toward the next generation of negative symptom assessments: the collaboration to advance negative symptom assessment in schizophrenia. Schizophr Bull. 2011;37(2):291–299.
   PubMed Web of Science ®Google Scholar
• Makinen J, Miettunen J, Jaaskelainen E, et al. Negative symptoms and their predictors in schizophrenia within the Northern Finland 1966 Birth Cohort. Psychiatry Res. 2010;178(1):121–125.
   Web of Science ®Google Scholar
• Hovington CL, Lepage M. Neurocognition and neuroimaging of persistent negative symptoms of schizophrenia. Expert Rev Neurother. 2012;12(1):53–69.
   PubMed Web of Science ®Google Scholar
• Carbon M, Correll CU. Thinking and acting beyond the positive: the role of the cognitive and negative symptoms in schizophrenia. CNS Spectr. 2014;19(Suppl 1): 38–52. quiz 35–7, 53.
   Google Scholar
• Millier A., Horváth M., Ma F., et al. Healthcare resource use in schizophrenia, EuroSC findings. J Market Access Health Policy. 2017;5:1372027.
   Google Scholar
• Selten JP, Wiersma D, van den Bosch RJ. Discrepancy between subjective and objective ratings for negative symptoms. J Psychiatr Res. 2000;34(1):11–13.
   PubMed Web of Science ®Google Scholar
• Makinen J, Miettunen J, Isohanni M, et al. Negative symptoms in schizophrenia: a review. Nord J Psychiatry. 2008;62(5):334–341.
   PubMed Web of Science ®Google Scholar
• Bottlender R, Sato T, Groll C, et al. Negative symptoms in depressed and schizophrenic patients: how do they differ? J Clin Psychiatry. 2003;64(8):954–958.
   Web of Science ®Google Scholar
• Willke RJ. Measuring the value of treatment to patients: patient-reported outcomes in drug development. Am Health Drug Benefits 2008 [Last Modified: November 10, 2011]; 1(1):34–40.
   PubMedGoogle Scholar
• European Medicines Agency. Committee for Medicinal Products for Human use (CHMP): “Reflection paper on the regulatory guidance for the use of health-related quality of life (HRQL) measures in the evaluation of medicinal products”. 27 July 2005 [Last accessed 2013 Jan 29]. Available from: https://www.ispor.org/workpaper/research_practices/proconcepts_definitions.pdf
   Google Scholar
• U.S Department of Health and Human Services Food and Drug Administration Guidance for Industry: “Patient-reported outcome measures. use in medical product development to support labeling claims”.December 2009 [Last accessed 2013 Jan 29]. Available from: http://www.fda.gov/downloads/Drugs/Guidances/UCM193282.pdf
   Google Scholar
• Schipper H, Clinch JJ, Olweny CLM. Quality of life studies: definitions and conceptual issues. In: Spilker B, editor. Quality of Life and Pharmacoeconomics in Clinical Trials. Philadelphia: Lippincott-Raven Publishers; 1996. p. 11–23.
   Google Scholar
• International Society for Quality of Life Research (ISOQOL). Health related of quality of life research. Available in: http://www.isoqol.org/about-isoqol/what-is-health-related-quality-of-life-research.
   Google Scholar
• Acquadro C, Berzon R, Dubois D, et al. Incorporating the patient’s perspective into drug development and communication: an ad hoc task force report of the Patient-Reported Outcomes (PRO) Harmonization Group meeting at the Food and Drug Administration, February 16, 2001. Value Health. 2003;6(5):522–531.
   PubMed Web of Science ®Google Scholar
• Millier A, Clay E, Charaf I, et al. Outcomes instruments in schizophrenia: a review of psychometric properties. Open J Med Psychol. 2014;3(2):141–156.
   Google Scholar
• Boyer L, Simeoni MC, Loundou A, et al. The development of the S-QoL 18: a shortened quality of life questionnaire for patients with schizophrenia. Schizophr Res. 2010;121(1–3):241–250.
   PubMed Web of Science ®Google Scholar
• Carlson J, Ochoa S, Haro JM, et al. Adaptation and validation of the quality-of-life scale: satisfaction with Life Domains Scale by Baker and Intagliata. Compr Psychiatry. 2009;50(1):76–80.
   Web of Science ®Google Scholar
• Franz M, Fritz M, Gallhofer B, et al. QLiS–development of a schizophrenia-specific quality-of-life scale. Health Qual Life Outcomes. 2012;10:61.
   Web of Science ®Google Scholar
• Franz M, Fritz M, Meyer T. Discriminant and convergent validity of a subjective quality-of-life instrument aimed at high content validity for schizophrenic persons. Qual Life Res. 2013;22(5):1113–1122.
   Web of Science ®Google Scholar
• Auquier P, Simeoni MC, Sapin C, et al. Development and validation of a patient-based health-related quality of life questionnaire in schizophrenia: the S-QoL. Schizophr Res. 2003;63(1–2):137–149.
   PubMed Web of Science ®Google Scholar
• Baker F, Intagliata J. Quality of life in the evaluation of community support systems. Eval Progr Plann. 1982;5:69–79.
   PubMedGoogle Scholar
• Awad AG, Voruganti LN, Heslegrave RJ. A conceptual model of quality of life in schizophrenia: description and preliminary clinical validation. Quality Life Research: International Journal Quality Life Aspects Treatment, Care Rehabilitation. 1997;6(1):21–26.
   Web of Science ®Google Scholar
• Baumstarck K, Boucekine M, Boyer L., et al. Quantification of relevance of quality of life assessment for patients with cognitive impairment: the suitability indices. BMC Neurol. 2014;14:78.
   Web of Science ®Google Scholar
• Baumstarck K, Boyer L, Boucekine M, et al. Self-reported quality of life measure is reliable and valid in adult patients suffering from schizophrenia with executive impairment. Schizophr Res. 2013;147(1):58–67.
   PubMed Web of Science ®Google Scholar
• Savill M, Orfanos S, Reininghaus U, et al. The relationship between experiential deficits of negative symptoms and subjective quality of life in schizophrenia. Schizophr Res. 2016;176(2–3):387–391.
   Web of Science ®Google Scholar
• Storf M The impact of FDA and EMA guidances regarding Patient Reported Outcomes (PRO) on the drug development and approval process. Scientific examination work to obtain the title “Master of Drug Regulatory Affairs”. 2013.
   Google Scholar
• Haro JM, Altamura C, Corral R, et al. Understanding the impact of persistent symptoms in schizophrenia: cross-sectional findings from the Pattern study. Schizophr Res. 2015;169(1–3):234–240.
   Web of Science ®Google Scholar
• Harvard health publications, the negative symptoms of schizophrenia, 2006 update. The Family Health Guide. Boston, MA; 2006.
   Google Scholar
• Velligan DI, Alphs L, Lancaster S, et al. Association between changes on the Negative Symptom Assessment scale (NSA-16) and measures of functional outcome in schizophrenia. Psychiatry Res. 2009;169(2):97–100.
   Web of Science ®Google Scholar
• Kinon BJ, Noordsy DL, Liu-Seifert H, et al. Randomized, double-blind 6-month comparison of olanzapine and quetiapine in patients with schizophrenia or schizoaffective disorder with prominent negative symptoms and poor functioning. J Clin Psychopharmacol. 2006;26(5):453–461.
   Web of Science ®Google Scholar
• Rabinowitz J, Berardo CG, Bugarski-Kirola D, et al. Association of prominent positive and prominent negative symptoms and functional health, well-being, healthcare-related quality of life and family burden: a CATIE analysis. Schizophr Res. 2013;150(2–3):339–342.
   PubMed Web of Science ®Google Scholar
• Levine SZ, Leucht S. Identifying clinically meaningful symptom response cut-off values on the SANS in predominant negative symptoms. Schizophr Res. 2013;145(1–3):125–127.
   Web of Science ®Google Scholar
• Wobrock T, Guse B, Cordes J, et al. Left prefrontal high-frequency repetitive transcranial magnetic stimulation for the treatment of schizophrenia with predominant negative symptoms: a sham-controlled, randomized multicenter trial. Biol Psychiatry. 2015;77(11):979–988.
   PubMed Web of Science ®Google Scholar
• Cordes J, Falkai P, Guse B, et al. Repetitive transcranial magnetic stimulation for the treatment of negative symptoms in residual schizophrenia: rationale and design of a sham-controlled, randomized multicenter study. Eur Arch Psychiatry Clin Neurosci. 2009;259(Suppl 2):S189–97.
   Google Scholar
• Schoemaker JH, Jansen WT, Schipper J, et al. The selective glycine uptake inhibitor org 25935 as an adjunctive treatment to atypical antipsychotics in predominant persistent negative symptoms of schizophrenia: results from the GIANT trial. J Clin Psychopharmacol. 2014;34(2):190–198.
   PubMed Web of Science ®Google Scholar
• Hirayasu Y, Sato S, Takahashi H, et al. A double-blind randomized study assessing safety and efficacy following one-year adjunctive treatment with bitopertin, a glycine reuptake inhibitor, in Japanese patients with schizophrenia. BMC Psychiatry. 2016;16:66.
   PubMed Web of Science ®Google Scholar
• Kay SR, Fiszbein A, Opler LA. The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987;13(2):261–276.
   PubMed Web of Science ®Google Scholar
• Guy W. ECDEU assessment manual for psychopharmacology, revised. Rockville: US Department Health, Education, and Welfare publication; 1976. p. 218–222.
   Google Scholar
• Addington D, Addington J, Maticka-Tyndale E. Assessing depression in schizophrenia: the Calgary Depression Scale. Br Journal Psychiatry Suppl. 1993;22:39–44.
   Google Scholar
• Chouinard G, Annable L, Jones BD. The extrapyramidal symptom rating scale. Canadian Journal of Neurological Sciences. 1980;22:39–44.
   Google Scholar
• Rothman M, Burke L, Erickson P, et al. Use of existing patient-reported outcome (PRO) instruments and their modification: the ISPOR Good Research Practices for Evaluating and Documenting Content Validity for the Use of Existing Instruments and Their Modification PRO Task Force Report. Value Health. 2009;12(8):1075–1083.
   PubMed Web of Science ®Google Scholar
• Haynes SN, Richard DCS, Kubany ES. Content validity in psychological assessment: A functional approach to concepts and methods. Psychol Assess. 1995;7(3):238–247.
   Web of Science ®Google Scholar
• Miller MJ. RES 600: Graduate Research Methods. Western International University; 2011. Available from: http://michaeljmillerphd.com/res500_lecturenotes/reliability_and_validity.pdf
   Google Scholar
• Terre M, Blanche KD. RiPAMftSS. 2nd ed. UTC Press; 2008.
   Google Scholar
• Stratford PW, Binkley JM, Riddle DL, et al. Sensitivity to change of the Roland-Morris Back Pain Questionnaire: part 1. Phys Ther. 1998;78(11):1186–1196.
   PubMed Web of Science ®Google Scholar
• Hersen M. CsHoABA. San Diego: Elsevier Academic Press, 2006, p. 32.
   Google Scholar
• Prieto L, Novick D, Sacristan JA, et al. Rasch model analysis to test the cross-cultural validity of the EuroQoL-5D in the Schizophrenia Outpatient Health Outcomes Study. Acta Psychiatrica Scandinavica Supplementum. 2003(416):24–29.
   Google Scholar
• Ware JE, Snow KK, Kolinski M, et al. SF-36 Health Survey Manual and Interpretation Guide. Boston: The Health Institute, New England Medical Centre, Boston; 1993.
   Google Scholar
• The WHOQOL Group. The World Health Organization Quality of Life Assessment (WHOQOL). Development and psychometric properties. Soc Sci Med. 1998;46(12):1569–1585.
   Web of Science ®Google Scholar
• Skevington SM, Lotfy M, O’Connell KA. The World Health Organization’s WHOQOL-BREF quality of life assessment: psychometric properties and results of the international field trial. A report from the WHOQOL group. Quality of life research: an international journal of quality of life aspects of treatment. Care and Rehabilitation. 2004;13(2):299–310.
   Google Scholar
• Lancon C, Auquier P, Launois R, et al. [Evaluation of the quality of life of schizophrenic patients: validation of the brief version of the Quality of Life Interview]. L’Encephale. 2000;26(4):11–16.
   Web of Science ®Google Scholar
• Oliver J, Huxley PJ, Priebe S, et al. Measuring the quality of life of severely mentally ill people using the Lancashire Quality of Life Profile. Socio Psychiatry Psychiatr Epidemiol. 1997;32:76–83.
   PubMed Web of Science ®Google Scholar
• Priebe S, Huxley P, Knight S, et al. Application and results of the Manchester Short Assessment of Quality of Life (MANSA). Int J Soc Psychiatry. 1999;45(1):7–12.
   PubMed Web of Science ®Google Scholar
• Naber D, Moritz S, Lambert M, et al. Improvement of schizophrenic patients’ subjective well-being under atypical antipsychotic drugs. Schizophr Res. 2001;50(1–2):79–88.
   PubMed Web of Science ®Google Scholar
• de Haan L, Weisfelt M, Dingemans PM, et al. Psychometric properties of the Subjective Well-Being Under Neuroleptics scale and the Subjective Deficit Syndrome Scale. Psychopharmacology. 2002;162(1):24–28.
   Web of Science ®Google Scholar
• Montejo AL, Lauffer JC, Cuervo J, et al. Validation of a specific measure to assess health-related quality of life in patients with schizophrenia and bipolar disorder: the ‘Tolerability and quality of life’ (TOOL) questionnaire. Ann Gen Psychiatry. 2011;10:6.
   Web of Science ®Google Scholar
• Montejo AL, CorreasLauffer J, Porras F, et al. Spanish validation of tool questionnaire: a new instrument to assess quality of life in patients with schizophrenia and bipolar disorder. Eur Psychiatry. 2009;24(1):S947.
   Google Scholar
• Diaz P, Mercier C, Hachey R, et al. An evaluation of psychometric properties of the client’s questionnaire of the Wisconsin Quality of Life Index-Canadian version (CaW-QLI). Qual Life Res. 1999;8(6):509–514.
   Web of Science ®Google Scholar
• Nadalet L, Kohl FS, Pringuey D, et al. Validation of a subjective quality of life questionnaire (S.QUA.LA) in schizophrenia. Schizophr Res. 2005;76(1):73–81.
   Web of Science ®Google Scholar
• Pitkanen A, Valimaki M, Endicott J, et al. Assessing quality of life in patients with schizophrenia in an acute psychiatric setting: reliability, validity and feasibility of the EQ-5D and the Q-LES-Q. Nord J Psychiatry. 2012;66(1):19–25.
   PubMed Web of Science ®Google Scholar
• Ritsner M, Kurs R, Gibel A, et al. Validity of an abbreviated quality of life enjoyment and satisfaction questionnaire (Q-LES-Q-18) for schizophrenia, schizoaffective, and mood disorder patients. Qual Life Res. 2005;14(7):1693–1703.
   Web of Science ®Google Scholar
• Wilkinson G, Hesdon B, Wild D, et al. Self-report quality of life measure for people with schizophrenia: the SQLS. Br J Psychiatry. 2000;177:42–46.
   PubMed Web of Science ®Google Scholar
• Kaneda Y, Imakura A, Fujii A, et al. Schizophrenia Quality of Life Scale: validation of the Japanese version. Psychiatry Res. 2002;113(1–2):107–113.
   Web of Science ®Google Scholar